Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | SPHK2 | Q9NRA0 | 4/20 | 0.40 |
| ▸ | SPHK1 | Q9NYA1 | 4/20 | 0.40 |
| ▸ | CETP | P11597 | 3/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.40 |
| ▸ | GMNN | O75496 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | GLA | P06280 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | THRB | P10828 | 2/20 | 0.40 |
| ▸ | CXCR5 | P32302 | 2/20 | 0.40 |
| ▸ | CCR6 | P51684 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL691873 | 1.00 | MEN1 (0.46) | MEN1KMT2ACYP3A4PTGS1PPARG | |
| SCHEMBL693426 | 0.88 | MEN1 (0.34) | MEN1KMT2ACYP3A4PTGS1PPARG | |
| SCHEMBL10897482 | 0.82 | ABCG2 (0.49) | MEN1KMT2ACYP3A4PTGS1PPARG | |
| SCHEMBL10897479 | 0.82 | ABCG2 (0.49) | MEN1KMT2ACYP3A4PTGS1PPARG | |
| SCHEMBL2839828 | 0.78 | MEN1 (0.52) | MEN1KMT2ACYP3A4PTGS1PPARG | |
| SCHEMBL9080744 | 0.78 | MEN1 (0.47) | MEN1KMT2ACYP3A4PTGS1PPARG | |
| SCHEMBL28921995 | 0.76 | MEN1 (0.50) | MEN1KMT2ACYP3A4PTGS1PPARG | |
| SCHEMBL78592 | 0.75 | — | — | |
| SCHEMBL78593 | 0.75 | — | — | |
| SCHEMBL873608 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160303243-A1 | ANIONIC CONJUGATES OF GLYCOSYLATED BACTERIAL METABOLITE | GLYCAN BIOSCIENCES LLC (US) | 2016-10-20 | — | — | US | disclosed |
| US-9346845-B2 | Anionic conjugates of glycosylated bacterial metabolite | GLYCAN BIOSCIENCES LLC (US) | 2016-05-24 | — | — | US | disclosed |
| US-20140323422-A1 | Anionic Conjugates of Glycosylated Bacterial Metabolite | Glycosynnovations Pty Ltd (AU) | 2014-10-30 | — | — | US | disclosed |
| US-8791245-B2 | Anionic conjugates of glycosylated bacterial metabolite | Glycan Bioscience LLC (US) | 2014-07-29 | — | — | US | disclosed |
| EP-2421877-A1 | ANIONIC CONJUGATES OF GLYCOSYLATED BACTERIAL METABOLITE | Glycan Biosciences Pty Ltd (AU) | 2012-02-29 | — | — | EP | disclosed |
| US-20110190233-A1 | ANIONIC CONJUGATES OF GLYCOSYLATED BACTERIAL METABOLITE | GLYCAN BIOSCIENCES PTY LTD (AU) | 2011-08-04 | — | — | US | disclosed |
| WO-2010037179-A1 | ANIONIC CONJUGATES OF GLYCOSYLATED BACTERIAL METABOLITE | GLYCAN BIOSCIENCES PTY LTD (AU) | 2010-04-08 | — | — | WO | disclosed |
| US-7205333-B2 | Therapy for influenza virus; inhaler | BIOTA SCIENTIFIC MANAGEMENT PTY. LTD. (AU) | 2007-04-17 | — | — | US | disclosed |
| US-7101909-B2 | Compound of a ligand of 2-methoxy methylester-6-fluoronaphthalene, an aryl ligand and a linker; each ligand domain capable of binding to a Ca++ channel | THERAVANCE, INC. (US) | 2006-09-05 | — | — | US | disclosed |
| US-7067620-B2 | Antibacterial agents | THERAVANCE, INC. (US) | 2006-06-27 | — | — | US | disclosed |
| WO-1999064045-A1 | NOVEL THERAPEUTIC AGENTS FOR MEMBRANE TRANSPORTERS | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | disclosed |
| WO-1999064050-A1 | NOVEL POTASSIUM CHANNEL DRUGS AND THEIR USES | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | disclosed |
| WO-1999063984-A1 | NOVEL SODIUM CHANNEL DRUGS AND USES | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | disclosed |
| WO-1999063992-A1 | NOVEL CALCIUM CHANNEL DRUGS AND USES | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | disclosed |
| WO-1999063930-A2 | NOVEL ANGIOTENSIN RECEPTOR MODULATORS AND THEIR USES | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | disclosed |
| WO-1999064051-A1 | NOVEL ANTIBACTERIAL COMPOUNDS | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | disclosed |
| WO-1999064040-A1 | NOVEL POLYENE MACROLIDE COMPOUNDS AND USES | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | disclosed |
| WO-1999051565-A9 | NOVEL LOCAL ANESTHETIC COMPOUNDS AND USES | ADVANCED MEDICINE INC (US) | 1999-12-02 | — | — | WO | disclosed |
| WO-1999051565-A1 | NOVEL LOCAL ANESTHETIC COMPOUNDS AND USES | ADVANCED MEDICINE, INC. (US) | 1999-10-14 | — | — | WO | disclosed |
| WO-1999042476-A1 | NOVEL ANTIBACTERIAL AGENTS | ADVANCED MEDICINE, INC. (US) | 1999-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190233-A1 | ANIONIC CONJUGATES OF GLYCOSYLATED BACTERIAL METABOLITE | GNE, CD44, FUT5 | MEN1 1514/4885KMT2A 2624/4885CYP3A4 2423/4885 |
| US-20160303243-A1 | ANIONIC CONJUGATES OF GLYCOSYLATED BACTERIAL METABOLITE | GNE, CD44, FUT5 | MEN1 1514/4885KMT2A 2624/4885CYP3A4 2423/4885 |
| US-20140323422-A1 | Anionic Conjugates of Glycosylated Bacterial Metabolite | GNE, CD44, FUT5 | MEN1 1514/4885KMT2A 2624/4885CYP3A4 2423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.